Barbara Green, MD
Neurology · Chesterfield, MONPI 1497783997
Payments from drug & device makers
Across 680 payments — averaging $894.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$217K
- Biogen$114K
- EMD Serono, Inc.$96K
- F. Hoffmann-la Roche AG$37K
- Sanofi$37K
- Novartis$26K
- plus $82K from 27 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 58 | $217,285 |
| Biogen | 91 | $113,571 |
| EMD Serono, Inc. | 138 | $95,717 |
| F. Hoffmann-la Roche AG | 2 | $36,644 |
| Sanofi | 55 | $36,552 |
| Novartis | 172 | $26,442 |
| E.r. Squibb & Sons, L.L.C. | 11 | $19,716 |
| Genentech USA, Inc. | 20 | $18,076 |
| Teva Pharmaceuticals USA, Inc. | 13 | $12,225 |
| Vanda Pharmaceuticals Inc. | 10 | $11,874 |
| Johnson & Johnson | 14 | $10,555 |
| Greenwich Biosciences, Inc. | 1 | $3,048 |
| TG Therapeutics, Inc. | 6 | $2,275 |
| Banner Life Sciences, LLC | 1 | $900 |
| Janssen Scientific Affairs, LLC | 1 | $850 |
| Amgen(2 entities) | 21 | $547 |
| AbbVie | 14 | $284 |
| AstraZeneca(2 entities) | 9 | $270 |
| Acadia Pharmaceuticals Inc | 14 | $267 |
| Genentech, Inc. | 4 | $199 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $103 |
| Lilly USA, LLC | 4 | $86 |
| Otsuka America Pharmaceutical, Inc. | 3 | $66 |
| Sanofi-aventis U.S. LLC | 1 | $60 |
| Biohaven Pharmaceuticals, Inc. | 1 | $56 |
| Avanir Pharmaceuticals, Inc. | 3 | $53 |
| Pfizer | 3 | $44 |
| Supernus Pharmaceuticals, Inc. | 2 | $43 |
| MDD US Operations, LLC | 2 | $43 |
| Acorda Therapeutics, Inc | 2 | $32 |
| Lundbeck LLC | 1 | $22 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
| Bayer | 1 | $14 |
How this compares
$607,939 in reported general payments places this provider in the 90th percentile of 381 neurology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in Chesterfield
- William RosenfeldChesterfield$2.3M
- Max BenzaquenChesterfield$296K
- Randall BatemanSaint Louis$92.3M
- David HoltzmanSaint Louis$25.2M
- Robert NaismithSaint Louis$13.8M
- Eric McDadeSaint Louis$9.6M
- Robert BucelliSaint Louis$8.5M
- Barbara SniderSaint Louis$7M
- Curtis SchreiberBolivar$6.4M
- Gregory WuSaint Louis$5.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.